IMARA Inc. has a market-cap of $277.5 million.
Morgan Stanley, Citigroup and SVB Leerink served as the underwriters for the IPO.
IMARA Inc. provided the following description of their company for its IPO: ” We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease, or SCD, and b-thalassemia. IMR-687 is a highly selective, potent small molecule inhibitor of phosphodiesterase-9, or PDE9, that has a multimodal mechanism of action that acts primarily on red blood cells, or RBCs, and has the potential to act on white blood cells, or WBCs, adhesion mediators and other cell types that are implicated in these disorders. “.
IMARA Inc. was founded in 2016 and has 20 employees. The company is located at 116 Huntington Avenue, 6th Floor, Boston, MA 02116, US and can be reached via phone at (617) 206-2020 or on the web at http://www.imaratx.com.
Receive News & Ratings for IMARA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMARA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.